Pharmacokinetic Analysis of Levofloxacin in Healthy Korean Volunteers

다국어 초록 (Multilingual Abstract)

A sensitive and simple method of determining the plasma levofloxacin (LFX, CAS 100986-85-4) concentrations in human volunteers by liquid-liquid extraction were developed and validated by using a high-performance liquid
chromatography/diode array detector. The method was also applied to armacokinetic study of LFX. LFX was orally administered to 8 healthy male Korean volunteers at single lowest dose of 200 mg, compared to the published reports in which more than 500 mg of LFX was orally administered. LFX in human plasma was determined. The detection limit of LFX was 0.05 μg/mL. Cmax value was 2.48 ± 0.67 μg/mL. AUC0→24 hr and AUC0→∞ were 14.52 ± 3.35 μg/mL and 16.00 ± 3.66 μg · hr/mL, respectively. The terminal half-life was 6.87±0.46 hr. Our pharmacokinetic parameters were very consistent
with that previously reported, showing good correlation between LFX doses and AUC (r2=0.995). This method can be useful for the pharmacokinetics and bioequivalence study with relatively low dose for reducing the main side effects of LFX.

참고문헌 (Reference)

1 H. Liang, "Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human serum" 772 : 53-63, 2002

2 F.A.Wong, "Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human serum and urine" 15 : 765-771, 1997

3 M. Furlanut, "Pharamcokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections" 51 : 101-106, 2003

4 E.M. Grant, "Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition" 41 (41): 206-209, 2001

5 K. Sato, "In vitro and in vivo activity of DL-8280, a new oxazine derivative" 22 : 548-553, 1982

6 O. Okazaki, "High-performance liquid chromatographic determination of (S)-(-)-ofloxacin and its metabolites in serum and urine using a solid-phase clean-up" 563 : 313-322, 1991

7 S.C. Chien, "Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob" 42 (42): 885-888, 1998

8 J. Macek, "Determination of ofloxacin in human serum using high-performance liquid chromatography and fluorescence detection, J. Chromatogr" 673 (673): 316-319, 1995

9 T. Ohkubo, "Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching" 573 : 289-293, 1992

10 S. Djabarouti, "Determination of levofloxacin in serum, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method" 799 : 165-172, 2004

11 A. Lubasch, "Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers, Antimicrob" 44 (44): 2600-2603, 2000

12 L. Shargel, "Chapter 10. Bioavailability and bioequivalence, In Applied biopharmaceutics and Pharmacokineti" Appleton & Lange 193-, 193

13 S. Bottcher, "An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum" 25 (25): 197-203, 2001